Company:  PROTHENA CORP PUBLIC LTD ... (PRTA)
Form Type:  4
Filing Date:  8/5/2022 
CIK:  0001559053 
Address:  77 SIR JOHN ROGERSON'S QUAY, BLOCK C
GRAND CANAL DOCKLANDS
 
City, State, Zip:  DUBLIN 2,  D02 VK60 
Telephone:  011-353-1-236-2500 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$33.11  
Change: 
0.85 (2.64%)  
Trade Time: 
Aug 05  
Market Cap: 
$1.55B
Trade PRTA now with 

© 2022  
Description of Business
Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. Fueled by our deep scientific expertise built over decades of research, we are advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which our ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Our wholly-owned programs include birtamimab for the potential treatment of AL amyloidosis, a portfolio of programs for the potential treatment of Alzheimer's disease including PRX012 that targets A? (Amyloid beta) and a novel dual A?-Tau vaccine.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES